Potential Drug Interactions in Coronary Heart Disease Inpatients at RSUD PatutPatuh Patju
DOI:
https://doi.org/10.37824/8g7rmr79Keywords:
Coronary Heart Disease, Potential Drug Interactions, Polypharmacy, Patut Patuh Patju Regional Hospital.Abstract
Coronary heart disease (CHD) is the leading cause of death worldwide and requires long-term
therapy with a combination of several drugs, which increases the risk of potential drug interactions.
Evaluating potential drug interactions is essential to ensure therapeutic safety and prevent serious
adverse effects. This study aimed to identify the types and severity of potential drug interactions in
hospitalized CHD patients at Patut Patuh Patju Regional Hospital, West Lombok, in 2025. This
research employed a retrospective descriptive design based on the medical records of hospitalized
CHD patients from January to April 2025 who met the inclusion criteria. Data were analyzed using
Drugs.com to identify potential drug interactions and classify them according to severity. Of the 61
patients, the majority were male (57.5%) and aged 60–69 years (32.78%). All patients had
comorbidities, mainly hypercholesterolemia (48%), hypertension (35%), and diabetes mellitus
(17%). The most frequently prescribed drug classes were loop diuretics (14.74%), ACE inhibitors
(11.15%), and thiazide diuretics (9.15%). A total of 144 potential drug interactions were identified,
categorized as moderate (75.69%), major (15.27%), and minor (9.02%). The most common
interactions were atorvastatin–clopidogrel, furosemide–ramipril, and spironolactone–ramipril. The
level of potential drug interactions among hospitalized CHD patients at Patut Patuh Patju Regional
Hospital, West Lombok, was relatively high, with most classified as moderate. Close monitoring
and pharmaceutical interventions are required to minimize risks and enhance therapeutic safety.
References
[1] Avila, C., et al. (2020). Medication adherence in cardiovascular patients: A systematic review. Journal of Cardiology, 75(2), 123–132.
[2] Brunner, L. S., & Suddarth, D. S. (2018). Textbook of Medical-Surgical Nursing. Philadelphia: Lippincott Williams & Wilkins.
[3] Food and Drug Administration (FDA). (2016). FDA drug safety communication: Updated restrictions for simvastatin.
Retrieved from https://www.fda.gov
[4] Katzung, B. G. (2018). Basic and Clinical Pharmacology (14th ed.). McGraw-Hill Education.
[5] Kementerian Kesehatan Republik Indonesia. (2018). Riset Kesehatan Dasar (Riskesdas) 2018.
[6] Lestari, A., et al. (2022). Evaluasi potensi interaksi obat pada pasien jantung koroner di RS Baptis Kediri. Jurnal Farmasi Klinik Indonesia, 11(2), 145–
153.
[7] Sari, I. P. (2021). Evaluation of drug interactions among hypertensive patients in primary care. Jurnal Farmasi Klinik Indonesia, 10(1), 25–33.
[8] Nur’aini, N., Kuncoro, B., & Yanti, Y. (2019). Evaluasi potensi interaksi obat pada pasien jantung koroner rawat inap di RSUD Kabupaten Tangerang. Jurnal Ilmiah Farmasi, 15(1), 21–28.
[9] Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., ... & Wright, J. T. (2018). 2017
[10] Rahayu, S., et al. (2021). Epidemiologi penyakit jantung koroner di Indonesia. Jurnal Kesehatan Masyarakat Indonesia, 16(3), 211–220.
[11] Tatro, D. S. (2018). Drug Interaction Facts. St. Louis: Wolters Kluwer.
[12] World Health Organization. (2023). Cardiovascular diseases (CVDs) fact sheet. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
